BiTE | Blood Cancers Today

BiTE

First-in-Human Phase I Study Assesses ROR1-Targeting Bispecific T-Cell Engager in CLL/MCL

Kerri FitzgeraldChronic Lymphocytic Leukemia | February 1, 2023

The phase I/II study included patients with relapsed/refractory CLL or MCL who received two or more prior systemic therapies.